Cariprazine
- Generic Name
- Cariprazine
- Brand Names
- Vraylar, Reagila
- Drug Type
- Small Molecule
- Chemical Formula
- C21H32Cl2N4O
- CAS Number
- 839712-12-8
- Unique Ingredient Identifier
- F6RJL8B278
- Background
Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT receptors and as an antagonist at serotonin 5-HT receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.
- Indication
Cariprazine is indicated for the treatment of schizophrenia in adults to manage both positive and negative symptoms. It is also indicated to monotherapy for acute management of manic or mixed episodes associated with bipolar I disorder (bipolar mania) in adults, and acute management of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
- Associated Conditions
- Bipolar Disorder With Manic or Mixed Episodes, Depressive Episodes, Schizophrenia
- Associated Therapies
- -
The Zacks Analyst Blog: Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
The drug and biotech industry faced challenges due to political appointments, sales disappointments, and pipeline setbacks but is expected to recover by 2025. Innovation in rare diseases, oncology, and neuroscience, along with strong M&A activity, are key growth drivers. Despite headwinds like patent cliffs and regulatory risks, companies like Eli Lilly, J&J, AbbVie, AstraZeneca, and Pfizer remain strong investment choices due to their robust revenue streams and continuous R&D investments.
5 Large Drug Stocks to Keep An Eye On in the New Year
The drug and biotech industry faced challenges due to political appointments, sales disappointments, and pipeline setbacks but is expected to recover by 2025. Innovation in rare diseases, oncology, obesity, and neuroscience drives growth. Eli Lilly, J&J, AbbVie, AstraZeneca, and Pfizer are key players to watch.
4 Big Drug Stocks That May Continue to Outperform in 2025
The drug and biotech sector experienced a strong first half of 2024 with a 19.3% rise in the Zacks Large Cap Pharmaceuticals industry, driven by M&A, earnings, and regulatory successes. However, a downturn in the second half due to disappointing sales, guidance cuts, and pipeline setbacks led to an 11% decline. Despite this, Gilead, Eli Lilly, Vertex Pharmaceuticals, and AbbVie outperformed, with growth drivers like Gilead's HIV therapies, Lilly's tirzepatide medicines, Vertex's CF treatments, and AbbVie's new immunology drugs poised to sustain momentum into 2025.
Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar
Intra-Cellular Therapies seeks FDA approval for Caplyta as an adjunct treatment for major depressive disorder (MDD), potentially expanding its market to over $1 billion. Caplyta, already approved for schizophrenia and bipolar disorder, saw Q3 sales of $175 million, with Q4 projections at least $193 million. The MDD submission is based on Phase III trials showing symptom improvement when paired with an antidepressant. Jefferies estimates a 90–95% approval likelihood, predicting a company valuation of $9–12 billion. Intra-Cellular is also exploring Caplyta for autism and developing ITI-214 for Parkinson’s and ITI-333 for opioid use.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
AbbVie (NYSE: ABBV), Realty Income (NYSE: O), and Verizon Communications (NYSE: VZ) are recommended for long-term passive income due to their consistent dividend growth and strong financial positions.
Major Depressive Disorder Market to Register Immense Growth by 2034 Owing to a Robust Pipeline
New treatments like COMP360, Zuranolone, LY03005, REL-1017, Seltorexant, and ABV-1504 are expected to significantly transform the major depressive disorder (MDD) market. MDD affects 44 million diagnosed cases in the 7MM, with moderate cases being the most prevalent. Treatment approaches include pharmacological interventions, psychotherapy, and lifestyle changes. The market size for MDD is projected to grow from USD 7.1 billion in 2023, driven by disease awareness and new product launches.
AbbVie's $9B bet collapses as closely watched schizophrenia drug fails studies
AbbVie lost $40 billion in market value after its experimental drug emraclidine failed two clinical trials for schizophrenia. Despite the setback, AbbVie remains focused on neuroscience and has a diverse portfolio of brain medicines. The failure of emraclidine removes a competitive threat for Bristol Myers' Cobenfy, an approved antipsychotic.
AbbVie shares slip after schizophrenia drug trial misses primary endpoint
AbbVie's phase 2 trials for schizophrenia treatment, emraclidine, missed primary endpoint, causing share decline. Despite disappointment, AbbVie continues data analysis and remains committed to psychiatric and neurological disorder treatments.
Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings
Eli Lilly missed Q3 estimates, lowered guidance; Merck beat estimates, initiated phase III study; Pfizer beat estimates, raised 2024 guidance; AbbVie beat estimates, acquired Aliada, collaborated with EvolveImmune; Novartis beat estimates, raised 2024 expectations, FDA approved Scemblix expansion.
AbbVie, Gedeon Richter Ink Deal to Develop Novel Targets for Neuropsychiatric Conditions
AbbVie and Gedeon Richter expand their neuropsychiatric collaboration, aiming to discover and develop novel targets. The partnership includes preclinical and clinical R&D activities, with Richter receiving an upfront payment of $25 million and potential milestone payments. Vraylar, a product of their previous collaboration, has been approved for schizophrenia, bipolar I disorder, major depressive disorder, and as adjunctive therapy for MDD. The prevalence of mental illness in the U.S. in 2022 was over 20%, highlighting the need for new therapies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath